重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌

Clinical study of endostar combined with chemotherapy in relapsed advanced non-small cell lung cancer

目的观察重组人血管内皮抑素(恩度)联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法 11例复治的晚期NSCLC患者,接受恩度联合化疗治疗。恩度15mg/天,连续14天给药,间歇7天重复;同时,联合既往未使用或既往治疗病灶稳定的化疗药物。21天为1周期,2周期评价疗效。结果本组11例患者均可评价客观疗效和毒副反应。有效率(RR)为18.18%,疾病控制率(DCR)为81.82%;生活质量(QOL)改善者4例(36.4%),稳定者5例(45.4%),下降2例(18.2%)。主要毒副反应与化疗药物有关,包括白细胞减少2例(18.18%),恶心呕吐2例(18.18%)。与恩度有关的心脏毒副反应1例(9%),主要表现为疲乏感。出现皮肤一过性斑丘疹1例(9%)。结论恩度联合化疗治疗晚期NSCLC可以改善和稳定患者的生活质量,恩度与部分化疗药物有协同作用,安全性好。

Objective To observe the efficacy and safety of rh-endostatin injection（endostar） combined with chemotherapy on relapsed advanced non-small cell lung cancer（NSCLC）.Methods Endostar combined with routing chemotherapy agents were administrated to 11 patients with relapsed advanced NSCLC.The dosage of endostar was 15mg/day,day1-14 per cycle,and repeated 7days later.The chemotherapy agents which were not used before or not cross-resistant to pre-chemotherapeutic agents were selected to be given simultaneously.The combined regimen was repeated every 21 days.Toxicity was evaluated after one cycle and efficacy was evaluated after two cycles.Results All the cases were evaluable for efficacy and safety.The objective response rate（RR） was 18.18%and disease control rate（DCR） was 81.82%.The quality of life（QOL） were improved in 4 cases（36.4%）,stabled in 5 cases（45.4%）,and decreased in 2 cases（18.2%）.The toxicities were mainly related with the chemotherapy agents,including neutropenia（18.18%） and nausea/vomiting（18.18%）.The toxicities related with YH-16 were electrocardiogram changes,including non-specific T wave or ST-T changes（9%）.And 1 case appeared unabiding papule or macula.Conclusion The therapy of endostar combined with the related chemotherapy on the relapsed advanced NSCLC patients can improve and retain QOL.There is a synergetic effect between endostar and part of chemotherapy agents,which shows good safety.